XBiotech (NASDAQ:XBIT) Stock Passes Below Fifty Day Moving Average - Should You Sell?

Key Points

• Technical signal: XBiotech shares fell below their 50‑day moving average (50‑day = $2.35), trading as low as $2.31 and last at $2.33 on volume of 24,185, with the 50‑day also below the 200‑day ($2.45) indicating technical weakness.
• Analyst sentiment: Weiss Ratings reiterated a "Sell (D-)" and MarketBeat shows an average rating of Sell, with one analyst currently rating the stock a Sell.
• Fundamentals: XBiotech is a clinical‑stage biopharma with a market cap of about $71.0M, reported a quarterly loss of $0.88 per share and a negative P/E of -1.55, reflecting continued unprofitability.

XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.35 and traded as low as $2.31. XBiotech shares last traded at $2.33, with a volume of 24,185 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of XBiotech in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of "Sell".

XBiotech Stock Performance

The company's fifty day moving average is $2.35 and its two-hundred day moving average is $2.45. The company has a market cap of $71.04 million, a price-to-earnings ratio of -1.55 and a beta of 0.84.

XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings results on Friday, March 13th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter.

Hedge Funds Weigh In On XBiotech

Several hedge funds and other institutional investors have recently bought and sold shares of XBIT. Persistent Asset Partners Ltd purchased a new stake in XBiotech in the 4th quarter worth approximately $32,000. Bank of America Corp DE boosted its position in XBiotech by 41.5% in the 2nd quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 5,344 shares in the last quarter. XTX Topco Ltd purchased a new stake in XBiotech in the 2nd quarter worth approximately $61,000. BNP Paribas Financial Markets boosted its position in XBiotech by 27.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company's stock worth $62,000 after purchasing an additional 4,416 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in XBiotech in the 2nd quarter worth approximately $75,000. Institutional investors and hedge funds own 55.70% of the company's stock.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company's core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech's lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company's most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.